Respiratory syncytial virus (RSV) infection is a major concern for the population across all age groups and it is the single serotype with two major antigenic subgroups circulating together but one leads . Considering published outcomes related to treatment, as well as the impact of RSV on global healthcare, a promising treatment or vaccine development remains a priority. The potential of liposomes as a carrier of active pharmacological agents was described decades ago [2-4] whilst liposomes have attracted much attention for their ability to carry antigens as well as immunomodulators . Therefore, the work in this paper was aimed to prepare liposomes < 100 nm using thin film hydration followed by sonication, to effectively conjugate the anti-RSV peptide RF-482 and investigate the efficiency the liposomal formulation in presence and absence peptide RF-482 to inhibit RSV spread.
|Title of host publication||Biotech, Biomaterials and Biomedical - TechConnect Briefs 2017|
|Number of pages||4|
|Publication status||Published - 1 Jan 2017|
|Event||11th Annual TechConnect World Innovation Conference and Expo, Held Jointly with the 20th Annual Nanotech Conference and Expo, and the 2017 National SBIR/STTR Conference - Washington, United States|
Duration: 14 May 2017 → 17 May 2017
|Conference||11th Annual TechConnect World Innovation Conference and Expo, Held Jointly with the 20th Annual Nanotech Conference and Expo, and the 2017 National SBIR/STTR Conference|
|Period||14/05/17 → 17/05/17|
Bibliographical note© 2017 TechConnect.